- OPTIMA: Prosigna-Guided Chemotherapy Avoidance Shows Non-Inferior Outcomes in ER+/HER2− Early Breast Cancer Oncodaily
- Millions of breast cancer patients could safely avoid chemotherapy, study suggests BBC
- Groundbreaking genomic test could spare millions of breast cancer patients chemotherapy The Guardian
- Skip the chemo: Millions of breast cancer patients could be spared chemotherapy with groundbreaking genomic test The Times of India
- IBCFS With Prosigna-Guided Adjuvant Therapy Is Noninferior to Chemoendocrine Therapy in ER+/HER2– Early Breast Cancer OncLive
